Literature DB >> 31174019

Time course of cardiomyopathy induced by doxorubicin in rats.

Daniel J M Medeiros-Lima1, Jorge J Carvalho2, Eduardo Tibirica3, Juliana P Borges4, Cristiane Matsuura5.   

Abstract

BACKGROUND: Doxorubicin (DOX)-related cardiotoxicity may expose cancer survivors to increased risk of cardiovascular morbidity and mortality. Here, we characterized the time course of DOX-induced cardiomyopathy in rats.
METHODS: Sprague-Dawley male rats (12 wk old) received doxorubicin hydrochloride (1 mg/kg/d, ip) during 10 consecutive days and they were euthanized one (DOX1), two (DOX2) or four (DOX4) weeks after the last drug injection. Control group received NaCl 0.9% (ip). Hearts were mounted on a Langendorff perfusion system, left ventricle fragments were processed for microscopy and oxidative stress-related assays, and blood was collected for cardiac troponin I assay.
RESULTS: All DOX-treated groups showed swollen and vacuolated cardiomyocytes with myofilaments disarray and mitochondrial damage. These changes were already evident after one week and became more pronounced after four weeks. Cardiac troponin I plasma levels were significantly increased in DOX1 and further increased in DOX4 compared to control group. Increased oxidative damage to lipids was observed in DOX1, and to proteins in DOX4. Glutathione peroxidase activity increased in DOX4. The morphological changes resulted in cardiac remodeling, including interstitial fibrosis, apoptosis and significant impairment of both contractile and relaxation function in DOX 4 compared to control group. Hearts from all animals displayed an early reduction in the responsiveness to norepinephrine.
CONCLUSIONS: These findings support the view that DOX cardiotoxicity occurs in a "continuum", and as the hypothesis of an irreversible cardiac injury is being challenged, understanding the progression of morphological and functional changes caused by DOX may allow proper timing of initiation of prophylactic treatment.
Copyright © 2019 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiomyopathy; Cardiotoxic agents; Reactive oxygen species; Ventricular cardiac remodeling

Mesh:

Substances:

Year:  2019        PMID: 31174019     DOI: 10.1016/j.pharep.2019.02.013

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  6 in total

1.  Deleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat.

Authors:  Petr Kala; Hana Bartušková; Jan Piťha; Zdenka Vaňourková; Soňa Kikerlová; Šárka Jíchová; Vojtěch Melenovský; Lenka Hošková; Josef Veselka; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Olga Gawrys; Hana Maxová; Luděk Červenka
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

Review 2.  New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging.

Authors:  Farah Cadour; Franck Thuny; Joevin Sourdon
Journal:  Front Cardiovasc Med       Date:  2022-02-07

3.  Investigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model.

Authors:  Marah Freiwan; Mónika G Kovács; Zsuzsanna Z A Kovács; Gergő Szűcs; Hoa Dinh; Réka Losonczi; Andrea Siska; András Kriston; Ferenc Kovács; Péter Horváth; Imre Földesi; Gábor Cserni; László Dux; Tamás Csont; Márta Sárközy
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923

4.  Injection of Matrix Metalloproteinase-9 Leads to Ventricular Remodeling.

Authors:  Enzheng Zhu; Congcong Yuan; Simiao Hu; Yiling Liao; Bowei Li; Yuliang Zhou; Wanxing Zhou
Journal:  Dis Markers       Date:  2022-09-20       Impact factor: 3.464

Review 5.  Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician.

Authors:  Ekaterina Yu Podyacheva; Ekaterina A Kushnareva; Andrei A Karpov; Yana G Toropova
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

6.  Extracellular matrix remodeling in animal models of anthracycline-induced cardiomyopathy: a meta-analysis.

Authors:  Jan M Leerink; Mabel van de Ruit; Elizabeth A M Feijen; Leontien C M Kremer; Annelies M C Mavinkurve-Groothuis; Yigal M Pinto; Esther E Creemers; Wouter E M Kok
Journal:  J Mol Med (Berl)       Date:  2021-05-29       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.